secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110852
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports Q3 2025 net loss $12.9M; advances denifanstat + resmetirom combo trial
--------------------------------------------------------------------------------

- Net loss for Q3 2025 was $12.9M vs $14.6M YoY; nine-month net loss $41.5M vs $29.4M.
- Cash, cash equivalents and marketable securities totaled $125.5M as of Sept 30, 2025.
- Phase 1 PK trial of denifanstat plus resmetirom in MASH cirrhosis underway; data expected 1H 2026.
- Partner Ascletis completed pre-NDA consultation with China NMPA for denifanstat in acne vulgaris; NDA submission planned.
- Marie O'Farrell promoted to CSO and Liz Rozek to Chief Legal & Admin Officer effective Nov 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/0001104659-25-110852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer